<p>ImmunityBio, Inc.（纳斯达克代码：IBRX - 获取免费报告）的股票目前被六家研究公司给予了 “适度买入” 的平均推荐，MarketBeat 报道称。一位投资分析师对该股票给予了卖出评级，五位分析师则对该公司给予了买入评级。在过去一年中，覆盖该股票的经纪公司给出的平均一年目标价为 10.75 美元。</p>
<ul>
<li>生物科技突破：3 只具有巨大上涨潜力的股票</li>
</ul>
<p>最近，一些股票分析师对 IBRX 股票发布了报告。Weiss Ratings 在周一的报告中重申了对 ImmunityBio 股票的 “卖出（e+）” 评级。HC Wainwright 在 9 月 10 日的报告中重申了 “买入” 评级，并将 ImmunityBio 股票的目标价设定为 8.00 美元。D. Boral Capital 在周四的研究报告中重申了 “买入” 评级，并将 ImmunityBio 股票的价格目标设定为 24.00 美元。最后，Jefferies Financial Group 在周五的研究报告中重新发布了对 ImmunityBio 股票的 “买入” 评级。</p>
<p><strong>查看我们关于 ImmunityBio 的最新报告</strong></p>
<h2>ImmunityBio 股票上涨 8.9%</h2>
<ul>
<li>5 只空头头寸异常大的股票</li>
</ul>
<p>ImmunityBio 股票在周五的午盘交易中上涨了 0.20 美元，达到 2.39 美元。该公司交易了 16,029,761 股股票，而其平均交易量为 8,571,170 股。ImmunityBio 的一年低点为 1.83 美元，一年高点为 4.27 美元。该公司的市值为 23.5 亿美元，市盈率为-5.79，贝塔值为 0.10。该公司的 50 日简单移动平均线为 2.29 美元，200 日简单移动平均线为 2.53 美元。</p>
<p>ImmunityBio（纳斯达克代码：IBRX - 获取免费报告）最近一次发布财报是在 11 月 5 日。该公司报告的每股收益为（0.07 美元），超过了市场共识预期的（0.10 美元）3 美分。该公司在该季度的收入为 3206 万美元，而分析师的预期为 3188 万美元。平均而言，卖方分析师预测 ImmunityBio 在当前年度的每股收益为-0.92 美元。</p>
<h2>ImmunityBio 的机构交易</h2>
<ul>
<li>分析师预计这两只中型生物科技股票将上涨超过 50%</li>
</ul>
<p>大型投资者最近增加或减少了对该股票的持股。Slow Capital Inc. 在第三季度以约 25,000 美元的估值购买了 ImmunityBio 的新头寸。Truist Financial Corp 在第三季度购买了价值约 27,000 美元的 ImmunityBio 股票。瑞士人寿资产管理有限公司在第三季度以约 27,000 美元的估值购买了 ImmunityBio 的新头寸。Diversify Advisory Services LLC 在第二季度以约 27,000 美元的估值购买了 ImmunityBio 的新头寸。最后，Financial Enhancement Group LLC 在第二季度以约 28,000 美元的估值购买了 ImmunityBio 的新股份。机构投资者持有该公司 8.58% 的股票。</p>
<h2>ImmunityBio 公司简介</h2>
<p>（获取免费报告）</p>
<p>ImmunityBio, Inc. 是一家临床阶段的生物技术公司，致力于开发增强自然免疫系统以战胜癌症和传染病的疗法和疫苗。其生物产品候选者的开发平台包括抗体 - 细胞因子融合蛋白；DNA、RNA 和重组蛋白疫苗；以及细胞疗法。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 ImmunityBio</li>
<li>如何投资小型股</li>
<li>Chewy 股票刚刚发出了 2026 年的重大买入信号</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投资股票</li>
<li>尽管 AI 需求激增，博通在财报后下滑</li>
<li>为什么投资高收益股息股票？</li>
<li>高通刚被称为 AI 失败者——那它为什么在上涨？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUJSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUJSWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 ImmunityBio 吗？</h2>
<p>在你考虑 ImmunityBio 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 ImmunityBio 并不在名单上。</p>
<p>虽然 ImmunityBio 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IBRX

<p>ImmunityBio, Inc.（纳斯达克代码：IBRX）获得了六家研究公司的平均 “适度买入” 评级。一位分析师给予 “卖出” 评级，而五位分析师给予 “买入” 评级。平均一年期目标价为 10.75 美元。最近的报告包括来自 Weiss Ratings 的 “卖出” 评级，以及来自 HC Wainwright 和 D. Boral Capital 的 “买入” 评级。该股票上涨了 8.9%，至 2.39 美元，市值为 23.5 亿美元。机构投资者持有该股票的 8.58%。ImmunityBio 开发用于癌症和传染病的疗法和疫苗</p>

<p>Shares of ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) have been given an average recommendation of &#34;Moderate Buy&#34; by the six research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $10.75.</p>
<div class="lb-trans"><p>ImmunityBio, Inc.（纳斯达克代码：IBRX - 获取免费报告）的股票目前被六家研究公司给予了 “适度买入” 的平均推荐，MarketBeat 报道称。一位投资分析师对该股票给予了卖出评级，五位分析师则对该公司给予了买入评级。在过去一年中，覆盖该股票的经纪公司给出的平均一年目标价为 10.75 美元。</p>
</div><ul>
<li>Biotech Breakouts: 3 Stocks With Massive Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技突破：3 只具有巨大上涨潜力的股票</li>
</ul>
</div><p>A number of equities analysts have recently issued reports on IBRX shares. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of ImmunityBio in a report on Monday. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $8.00 target price on shares of ImmunityBio in a report on Wednesday, September 10th. D. Boral Capital reaffirmed a &#34;buy&#34; rating and set a $24.00 price objective on shares of ImmunityBio in a research note on Thursday. Finally, Jefferies Financial Group reissued a &#34;buy&#34; rating on shares of ImmunityBio in a research note on Friday.</p>
<div class="lb-trans"><p>最近，一些股票分析师对 IBRX 股票发布了报告。Weiss Ratings 在周一的报告中重申了对 ImmunityBio 股票的 “卖出（e+）” 评级。HC Wainwright 在 9 月 10 日的报告中重申了 “买入” 评级，并将 ImmunityBio 股票的目标价设定为 8.00 美元。D. Boral Capital 在周四的研究报告中重申了 “买入” 评级，并将 ImmunityBio 股票的价格目标设定为 24.00 美元。最后，Jefferies Financial Group 在周五的研究报告中重新发布了对 ImmunityBio 股票的 “买入” 评级。</p>
</div><p><strong>Check Out Our Latest Report on ImmunityBio</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 ImmunityBio 的最新报告</strong></p>
</div><h2>ImmunityBio Stock Up 8.9%</h2>
<div class="lb-trans"><h2>ImmunityBio 股票上涨 8.9%</h2>
</div><ul>
<li>5 Stocks with Unusually Large Short Interest</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只空头头寸异常大的股票</li>
</ul>
</div><p>ImmunityBio stock traded up $0.20 during mid-day trading on Friday, reaching $2.39. 16,029,761 shares of the company's stock were exchanged, compared to its average volume of 8,571,170. ImmunityBio has a one year low of $1.83 and a one year high of $4.27. The firm has a market capitalization of $2.35 billion, a PE ratio of -5.79 and a beta of 0.10. The business's fifty day simple moving average is $2.29 and its 200 day simple moving average is $2.53.</p>
<div class="lb-trans"><p>ImmunityBio 股票在周五的午盘交易中上涨了 0.20 美元，达到 2.39 美元。该公司交易了 16,029,761 股股票，而其平均交易量为 8,571,170 股。ImmunityBio 的一年低点为 1.83 美元，一年高点为 4.27 美元。该公司的市值为 23.5 亿美元，市盈率为-5.79，贝塔值为 0.10。该公司的 50 日简单移动平均线为 2.29 美元，200 日简单移动平均线为 2.53 美元。</p>
</div><p>ImmunityBio (NASDAQ:IBRX - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.03. The business had revenue of $32.06 million during the quarter, compared to analysts' expectations of $31.88 million. On average, sell-side analysts forecast that ImmunityBio will post -0.92 earnings per share for the current year.</p>
<div class="lb-trans"><p>ImmunityBio（纳斯达克代码：IBRX - 获取免费报告）最近一次发布财报是在 11 月 5 日。该公司报告的每股收益为（0.07 美元），超过了市场共识预期的（0.10 美元）3 美分。该公司在该季度的收入为 3206 万美元，而分析师的预期为 3188 万美元。平均而言，卖方分析师预测 ImmunityBio 在当前年度的每股收益为-0.92 美元。</p>
</div><h2>Institutional Trading of ImmunityBio</h2>
<div class="lb-trans"><h2>ImmunityBio 的机构交易</h2>
</div><ul>
<li>Analysts see over 50% gains in these 2 mid-cap biotech stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师预计这两只中型生物科技股票将上涨超过 50%</li>
</ul>
</div><p>Large investors have recently added to or reduced their stakes in the stock. Slow Capital Inc. bought a new position in ImmunityBio during the 3rd quarter valued at approximately $25,000. Truist Financial Corp purchased a new position in shares of ImmunityBio in the 3rd quarter worth about $27,000. Swiss Life Asset Management Ltd bought a new position in ImmunityBio in the 3rd quarter worth about $27,000. Diversify Advisory Services LLC bought a new position in ImmunityBio in the 2nd quarter worth about $27,000. Finally, Financial Enhancement Group LLC purchased a new stake in ImmunityBio during the 2nd quarter valued at about $28,000. Institutional investors own 8.58% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了对该股票的持股。Slow Capital Inc. 在第三季度以约 25,000 美元的估值购买了 ImmunityBio 的新头寸。Truist Financial Corp 在第三季度购买了价值约 27,000 美元的 ImmunityBio 股票。瑞士人寿资产管理有限公司在第三季度以约 27,000 美元的估值购买了 ImmunityBio 的新头寸。Diversify Advisory Services LLC 在第二季度以约 27,000 美元的估值购买了 ImmunityBio 的新头寸。最后，Financial Enhancement Group LLC 在第二季度以约 28,000 美元的估值购买了 ImmunityBio 的新股份。机构投资者持有该公司 8.58% 的股票。</p>
</div><h2>ImmunityBio Company Profile</h2>
<div class="lb-trans"><h2>ImmunityBio 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.</p>
<div class="lb-trans"><p>ImmunityBio, Inc. 是一家临床阶段的生物技术公司，致力于开发增强自然免疫系统以战胜癌症和传染病的疗法和疫苗。其生物产品候选者的开发平台包括抗体 - 细胞因子融合蛋白；DNA、RNA 和重组蛋白疫苗；以及细胞疗法。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than ImmunityBio</li>
<li>How to Invest in Small Cap Stocks</li>
<li>Chewy Stock Just Flashed a Major Buy Signal for 2026</li>
<li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li>
<li>Broadcom Slips Post-Earnings Even as AI Demand Goes Parabolic</li>
<li>Why Invest in High-Yield Dividend Stocks?</li>
<li>Qualcomm Just Got Called an AI Loser—So Why Is It Rallying?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 ImmunityBio</li>
<li>如何投资小型股</li>
<li>Chewy 股票刚刚发出了 2026 年的重大买入信号</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投资股票</li>
<li>尽管 AI 需求激增，博通在财报后下滑</li>
<li>为什么投资高收益股息股票？</li>
<li>高通刚被称为 AI 失败者——那它为什么在上涨？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUJSWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=IBRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ImmunityBio Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 ImmunityBio 吗？</h2>
</div><p>Before you consider ImmunityBio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 ImmunityBio 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 ImmunityBio 并不在名单上。</p>
</div><p>While ImmunityBio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 ImmunityBio 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

ImmunityBio 公司（NASDAQ: IBRX）被券商给予 “适度买入” 的平均评级